2-(5-羟基-4,6,7-三甲基-2,3-二氢-1-苯并呋喃-2-基)乙酸 | 139232-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2-(5-羟基-4,6,7-三甲基-2,3-二氢-1-苯并呋喃-2-基)乙酸
• 中文别名: 5-羟基-4,6,7-三甲基-(2,3-二氢苯并呋喃)-2-乙酸
• 英文名称: (+/-)-2,3-dihydro-5-hydroxy-4,6,7-trimethyl-2-benzofuranacetic acid
• 英文别名: 2-(5-hydroxy-4,6,7-trimethyl-2,3-dihydrobenzofuran-2-yl)acetic acid；(Rs)-2-(2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuranyl)-acetic acid；5-hydroxy-4,6,7-trimethyl-2,3-dihydrobenzofuran-2-acetic acid；2,3-dihydro-5-hydroxy-4,6,7-trimethylbenzofuran-2-ethanoic acid；2-(5-hydroxy-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-2-yl)acetic acid
• CAS: 139232-40-9
• 化学式: C₁₃H₁₆O₄
• 分子量: 236.268
• InChiKey: FUWYMDOAFXKROW-UHFFFAOYSA-N

物化性质

• 沸点：
  459.0±45.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(5-羟基-4,6,7-三甲基-2,3-二氢-1-苯并呋喃-2-基)乙酸 以84的产率得到2-(5-乙酰氧基-4,6,7-三甲基-2,3-二氢苯并呋喃-2-基)乙酸
  参考文献：
  名称：

  J. Heterocycl. Chem. 1993, 30, 679-689

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-methyl 4-(2,5-dihydroxy-3,4,6-trimethylphenyl)but-2-enoate 以56的产率得到2-(5-羟基-4,6,7-三甲基-2,3-二氢-1-苯并呋喃-2-基)乙酸
  参考文献：
  名称：

  J. Heterocycl. Chem. 1993, 30, 679-689

  摘要：

  DOI：

文献信息

• Synthesis of novel 2-substituted-5-oxycoumarans<i>via</i>A direct route to 2,3-dihydro-5-hydroxy-2-benzofuranacetic acids
  作者：Stefano Ceccarelli、Patrizia De Vellis、Romolo Scuri、Sergio Zanarella、Mario Brufani

  DOI：10.1002/jhet.5570300318

  日期：1993.5

  A number of novel 2-substituted 2,3-dihydro-5-benzofuranols optionally protected on 5-OH group have been prepared via a simple two step route to racemic 2,3-dihydro-5-hydroxy-2-benzofuranacetic acids from hydroquinones and 4-bromocrotonates.

  已经通过简单的两步路线从对苯二酚中生成外消旋的2,3-二氢-5-羟基-2-苯并呋喃乙酸，制备了许多新型的2-取代的2,3-取代的2,3-二氢-5-苯并呋喃醇，可任选地被5-OH保护。和4-溴巴豆酸盐。
• 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
  申请人：Cerebrus Pharmaceuticals Limited

  公开号：EP1006108A1

  公开（公告）日：2000-06-07

  A compound of the formula (1): wherein A is wherein R1, R2 and R3 are independently selected from H and alkyl; wherein X is O, S, NR4 or a direct bond, wherein R4 is H or alkyl; wherein Z is a saturated hydrocarbyl chain comprising from 1 to 20 carbon atoms interrupted by one or more heteroatom(s) and optionally substituted by one or more oxo substituent(s); wherein q is 1, 2 or 3; wherein if q is 2 or 3, then each A can be the same or different; wherein the or each R5 is independently selected from H and alkyl; wherein the or each R6 is independently selected from alkyl; wherein n is 1 to 5; wherein p is 0 to 4; and wherein the sum of n and p is less than 6, or a pharmaceutically acceptable salt thereof, and the use thereof in therapy, particularly for the treatment of a condition associated with oxidative stress, such as oxidative damage of the central nervous system or an acute or chronic neurological disorder such as traumatic brain injury, spinal cord injury, cerebral tumour, subharrachnoid haemorrage/cerebral vasospasm, cerebral ischaemia, stroke (ischaemic or haemorragic), Alzheimer's disease, Huntington's Disease, Parkinson's Disease, Friedrich's ataxia, motor neuron disease or multiple sclerosis.

  其中A为其中R1、R2和R3分别独立选择自H和烷基；其中X为O、S、NR4或直接键，其中R4为H或烷基；其中Z为由1至20个碳原子组成的饱和碳氢链，中断一个或多个杂原子，并且可选择地被一个或多个氧代取代基取代；其中q为1、2或3；如果q为2或3，则每个A可以相同也可以不同；其中每个R5独立选择自H和烷基；其中每个R6独立选择自烷基；其中n为1至5；其中p为0至4；且n和p的总和小于6，或其药学上可接受的盐，以及其在治疗中的用途，特别用于治疗与氧化应激有关的疾病，如中枢神经系统的氧化损伤或急性或慢性神经系统疾病，如创伤性脑损伤、脊髓损伤、脑肿瘤、蛛网膜下腔出血/脑血管痉挛、脑缺血、中风（缺血性或出血性）、阿尔茨海默病、亨廷顿病、帕金森病、弗里德里希共济失调、运动神经元疾病或多发性硬化症。
• 5-Hydroxy- and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofurane-acetic acids and their esters for treating and preventing diabetic complications
  申请人：Biomedica Foscama Industria Chimico-Farmaceutica S.p.A.

  公开号：EP0848953A1

  公开（公告）日：1998-06-24

  It is disclosed to the use of 5-hydroxy- and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofurane-acetic acids and their esters and of pharmaceutical formulations containing them as active ingredients in a therapy for treating and preventing chronic diabetic complications.

  本发明公开了 5-羟基和 5-乙酰氧基-2,3-二氢-4,6,7-三甲基-2-苯并呋喃乙酸及其酯类以及含有它们的药物制剂作为活性成分在治疗和预防慢性糖尿病并发症中的用途。
• Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
  申请人：——

  公开号：US20030134332A1

  公开（公告）日：2003-07-17

  Methods and kits are provided for diagnosing medical conditions of patients with a disease or condition characterized by endothelial dysfunction based on a nitric oxide bioactivity index. Nitric oxide bioactivity index is the ratio of the level of a nitric oxide-related product such as nitrate or nitrite to the level of an oxidant stress-related product such as isoprostane in plasma, urine, or another specimen from a patient. Methods are also provided for using the nitric oxide bioactivity index to treat patients with endothelial dysfunction and monitor the course of treatment.

  本发明提供了根据一氧化氮生物活性指数诊断以内皮功能障碍为特征的疾病或病症患者病情的方法和试剂盒。一氧化氮生物活性指数是患者血浆、尿液或其他标本中一氧化氮相关产物（如硝酸盐或亚硝酸盐）与氧化应激相关产物（如异前列腺烷）水平的比值。还提供了使用一氧化氮生物活性指数治疗内皮功能障碍患者和监测治疗过程的方法。
• Predicting outcome of hyperbaric oxygen therapy treatment with nitric oxide bioavailability
  申请人：——

  公开号：US20040112375A1

  公开（公告）日：2004-06-17

  Methods and kits are provided for determining whether a patient will respond favorably to hyperbaric oxygen therapy treatment. The method comprises the step of comparing nitric oxide production, a nitric oxide-related product level, and/or the nitric oxide bioactivity index in a specimen from a patient with a threshold value. If nitric oxide production, nitric oxide-related product level, and/or the nitric oxide bioactivity index (defined as “the level of a nitric oxide-related product to the level of an oxidant stress-related product”) is above the threshold value then the patient will respond favorably to hyperbaric oxygen therapy treatment. If nitric oxide production, nitric oxide-related product level, and/or the nitric oxide bioactivity index is approximately at or below the threshold value then the patient may not respond favorably to hyperbaric oxygen therapy treatment.

  提供了用于确定患者是否会对高压氧治疗产生良好反应的方法和试剂盒。该方法包括将患者标本中的一氧化氮产生量、一氧化氮相关产物水平和/或一氧化氮生物活性指数与阈值进行比较的步骤。如果一氧化氮产生量、一氧化氮相关产物水平和/或一氧化氮生物活性指数（定义为 "一氧化氮相关产物水平与氧化应激相关产物水平之比"）高于阈值，那么患者将对高压氧治疗产生良好反应。如果一氧化氮产生量、一氧化氮相关产物水平和/或一氧化氮生物活性指数大致处于或低于阈值，则患者可能不会对高压氧治疗产生良好反应。